Analyst picks & changes

Amgen Inc.

(AMGN), Thousand Oaks, Calif.

Business: Biopharmaceuticals

Oppenheimer & Co. analyst Matt Geller lowered his estimates in response to the company's 10-Q, which estimates lower revenues going forward. His 1998 EPS estimate is now $2.90, down from $3.06. He lowered his year-over-year estimated growth rate for

Epogen

erythropoietin from 15

Read the full 523 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE